A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patients

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 6, 2014, Pages 441-448

  Montgomery, A Bruce ^a   Vallance, Shirley ^b   Abuan, Tammy ^a   Tservistas, Markus ^c   Davies, Andrew ^b  

^a Cardeas Pharma   (United States)

^b ALFRED HOSPITAL   (Australia)

^c Pari Pharma GmbH   (Germany)

Author keywords

aerosol delivery; amikacin; fosfomycin; ventilator; ventilator associated pneumonia

Indexed keywords

AMIKACIN; FOSFOMYCIN; PLACEBO; AEROSOL; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ABSENCE OF SIDE EFFECTS; ADULT; AEROSOL; AGED; AIRWAY PRESSURE; ARTICLE; BREATHING RATE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG ASPIRATION; LUNG CLEARANCE; MALE; MEDICAL NEBULIZER; OXYGENATION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TRACHEOBRONCHITIS; VENTILATED PATIENT; VENTILATOR ASSOCIATED PNEUMONIA; VENTILATOR ASSOCIATED TRACHEOBRONCHITIS; ADVERSE EFFECTS; ARTIFICIAL VENTILATION; AUSTRALIA; BLOOD; BRONCHITIS; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG MONITORING; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; NEBULIZER; PNEUMONIA, VENTILATOR-ASSOCIATED; TRACHEITIS; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BRONCHITIS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG MONITORING; EQUIPMENT DESIGN; FOSFOMYCIN; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PNEUMONIA, VENTILATOR-ASSOCIATED; RESPIRATION, ARTIFICIAL; TRACHEITIS; VICTORIA;

EID: 84903151026     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1100     Document Type: Article

References (24)

1. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, and Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23-30
2. McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, and Montgomery AB: Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921-928
3. Abu-Salah T, and Dhand R: Inhaled antibiotic therapy for ventilator-Associated tracheobronchitis and ventilator-Associated pneumonia: an update. Adv Ther. 2011;28:728-747
4. Wood GC: Aerosolized antibiotics for treating hospitalacquired and ventilator-Associated pneumonia. Expert Rev Anti Infect Ther. 2011;9:993-1000
5. Arnold HM, Sawyer AM, and Kollef MH: Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-Associated pneumonia. Respir Care. 2012;57:1226-1233
6. LuQ, Luo R,Bodin L,Yang J, Zahr N, AubryA,Golmard JL, and Rouby JJ: Efficacy of high-dose nebulized colistin in ventilator-Associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117:1335-1347
7. Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, and Rouby JJ: Nebulized ceftazidime and amikacin in ventilatorassociated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011;184:106-115
8. Palmer LB, Smaldone GC, Chen JJ, Baram D, Duan T, Monteforte M, Varela M, Tempone AK, O'Riordan T, Daroowalla F, and Richman P: Aerosolized antibiotics and ventilator-Associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008;36:2008-2013
9. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, and Fridkin S; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities: Antimicrobial-resistant pathogens associated with healthcare-Associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14
10. Montgomery AB, Rhomberg P, Abuan T, and Jones R: Synergistic effects for a combination of amikacin and fosfomycin against selected resistant gram-negative pathogens. [Abstract 43023 and poster] Am J Respir Crit Care Med. 2013;187:A3236
11. Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, and Garcia MS: BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with gram-negative pneumonia. Intensive Care Med. 2012;38:263-271
12. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, and Davis RL: Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985;132:761-765
13. Miller DD, Amin MM, Palmer LB, Shah AR, and Smaldone GC: Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med. 2003;168:1205-1209
14. Clark R, Heslet L, Antonsen K, and Donehower B: Evaluation of the disposition and safety of tobramycin solution for inhalation in ventilator-Associated pneumonia or tracheobronchitis patients. [Poster] Presented at American Thoracic Society International Conference 2003, Seattle, WA.
15. Alvarez S, Jones M, and Berk SL: In vitro activity of fosfomycin, alone and in combination, against methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;28:689-690
16. Eschenbacher WL, Boushey HA, and Sheppard D: Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone. Am Rev Respir Dis. 1984;129: 211-215
17. Cohen IL, Weinberg PF, Fein IA, and Rowinski GS: Endotracheal tube occlusion associated with the use of heat and moisture exchangers in the intensive care unit. Crit Care Med. 1988;16:277-279
18. Hahn M, Tservistas M, Hetzer U, Seidler A, Grieblinger E, Keller M, and Knoch M: In vitro assessment of a novel nebulizer for mechanically ventilated patients based on the eFlow technology. J Aerosol Med Pulm Drug Deliv. 2009;22:187-188
19. Kollef MH: What is ventilator-Associated pneumonia and why is it important?. Respir Care. 2005;50:714-724
20. Amikacin sulfate injection, solution, package insert (Hospira Inc., Lake Forest, IL). Revised 2011
21. Fosfomycin tromethamine (Monurol) package insert (Forest Pharmaceuticals, Inc., St. Louis, MO). 2011
22. Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, Frossard M, Heinz G, and Mü ller M: Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother. 2003;51:1247-1252
23. Zhanel GG, Adam HJ, Low DE, Blondeau J, DeCorby M, Karlowsky JA, Weshnoweski B, Vashisht R, Wierzbowski A, and Hoban DJ: Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the Canward 2007-2009 study. Diagn Microbiol Infect Dis. 2011;69:291-306
24. Clinicaltrials.gov Identifier NCT 01969799